Loading…
Precision BioSciences, Inc. is projected to rise to $9.80 by 2027, a +40% move from its current price of $6.99. DTIL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $6.77 | $6.99 | $7.22 | +0.01% |
| Aug 5 | $6.69 | $6.99 | $7.31 | +0.02% |
| Aug 6 | $6.62 | $6.99 | $7.39 | +0.03% |
| Aug 7 | $6.56 | $6.99 | $7.45 | +0.04% |
| Aug 8 | $6.52 | $6.99 | $7.51 | +0.05% |
| Aug 9 | $6.47 | $6.99 | $7.56 | +0.06% |
| Aug 10 | $6.43 | $7.00 | $7.61 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.43 | $7.00 | $7.61 | +0.07% |
| Week 2 | $6.22 | $7.00 | $7.88 | +0.15% |
| Week 3 | $6.06 | $7.01 | $8.10 | +0.22% |
| Week 4 | $5.93 | $7.01 | $8.29 | +0.29% |
| Week 5 | $5.82 | $7.02 | $8.46 | +0.36% |
| Week 6 | $5.72 | $7.02 | $8.62 | +0.44% |
| Week 7 | $5.63 | $7.03 | $8.77 | +0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Precision BioSciences, Inc. is a clinical stage healthcare company focused on in vivo gene editing therapies. It develops ARCUS, a genome editing platform for DNA genome insertion, removal, and repair, targeting various genetic conditions in the United States.
The company’ s programs include PBGENE-HBV for the treatment of chronic hepatitis B virus to eliminate covalently closed circular DNA and to inactivate integrated HBV DNA, PBGENE-DMD (Excision) for Duchenne muscular dystrophy, PBGENE-3243 for mitochondrial diseases, and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. Precision BioSciences has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and with iECURE, Inc.
for ARCUS-mediated targeted gene insertion.
Incorporated in 2006, Precision BioSciences is headquartered in Durham, North Carolina, and is categorized within Healthcare.
DTIL is Precision BioSciences’ stock, currently trading at $7.36 with a market cap of $189.9M. It is ranked 3616 in market position among assets.
The price outlook, based on the provided forecast, shows a path of growth from a 2026 average of $7.36 toward higher averages and ranges in subsequent years, with notable bullish sentiment emerging from 2027 onward. By 2030, the forecast projects an average of $14.67 and a max of $23.11, with a 99.3% ROI. Long-range forecasts extend to 2040 and 2050 with an average of $37.22 (ROI 405.7%) and $80.10 (ROI 988.3%), respectively, both labeled as BULLISH.
A major floor 26.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 32.8% above — a clean break opens room to run.
A major ceiling 46.1% above — clearing it would confirm fresh momentum.
Key DTIL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DTIL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.06 | Sell | $7.08 | Sell |
| MA 10 | $7.22 | Sell | $7.29 | Sell |
| MA 20 | $7.95 | Sell | $7.51 | Sell |
| MA 50 | $7.34 | Sell | $7.40 | Sell |
| MA 100 | $7.10 | Sell | $6.95 | Buy |
| MA 200 | $6.03 | Buy | $6.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.90 | Neutral |
| Stoch RSI (14) | 7.63 | Buy |
| CCI (20) | -86.80 | Neutral |
| Williams %R (14) | -94.79 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -20.66 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 5.21 | Buy |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | -0.52 | Sell |
| Ultimate (7,14,28) | 25.25 | Buy |
| Momentum (10) | -0.88 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 6.89 | Buy |
| ADX (14) | 19.64 | Neutral |
| ATR (14) | 0.20 | Info |
Technical picture for DTIL over the next 30 days shows a BULLISH sentiment. The RSI14 is 40, with the 50-day simple moving average at $7.42 and the 200-day simple moving average at $5.96. Support is identified at $6.10 and resistance at $9.28.
The 30-day price range is $5.70 to $9.50, indicating consolidation around the current level with upside and downside potential within the defined band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.57 | $6.99 | $8.93 | 0% | Neutral | |
| $7.70 | $9.80 | $13.25 | +40% | Bullish | |
| $7.86 | $10.33 | $14.58 | +48% | Bullish | |
| $8.16 | $11.03 | $16.08 | +58% | Bullish | |
| $8.71 | $12.06 | $18.08 | +73% | Bullish | |
| $8.29 | $11.75 | $18.03 | +68% | Bullish | |
| $9.06 | $13.10 | $20.55 | +87% | Bullish | |
| $9.93 | $14.65 | $23.43 | +110% | Bullish | |
| $11.31 | $17.00 | $27.68 | +143% | Bullish | |
| $13.41 | $20.52 | $33.96 | +194% | Bullish | |
| $15.27 | $25.37 | $44.95 | +263% | Bullish | |
| $26.92 | $51.63 | $101.02 | +639% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.57 | $6.99 | $8.29 | +0.00% |
| September 2026 | $5.94 | $7.06 | $8.65 | +1.00% |
| October 2026 | $5.89 | $7.06 | $8.75 | -0.05% |
| November 2026 | $5.69 | $6.86 | $8.59 | -2.79% |
| December 2026 | $5.83 | $7.06 | $8.93 | +2.99% |
Click any year to see its month-by-month DTIL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DTIL to range from $3.57 to $8.93 through 2026. The $6.99 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DTIL price prediction for 2027 points to an average of $9.80 (low $7.70, high $13.25) — a potential gain of +40% on today's $6.99. Buyers look set to stay in control over this stretch.
In 2028, DTIL is projected to trade between $7.86 and $14.58, averaging $10.33 — a potential gain of +48% from today's $6.99. That is up +5% on the projected 2027 average. Momentum favours further upside here.
Precision BioSciences, Inc.'s 2029 outlook centres on $11.03, within a $8.16 to $16.08 range. That is up +7% on the projected 2028 average. That marks a +58% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DTIL could reach as high as $18.08, with a base case around $12.06 and support toward $8.71 — roughly +73% from $6.99. Momentum favours further upside here.
Expect DTIL to range from $8.29 to $18.03 through 2031. The $11.75 average target implies a +68% move from current prices. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The DTIL price prediction for 2032 points to an average of $13.10 (low $9.06, high $20.55) — a potential gain of +87% on today's $6.99. Momentum favours further upside here.
In 2033, DTIL is projected to trade between $9.93 and $23.43, averaging $14.65 — a potential gain of +110% from today's $6.99. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Precision BioSciences, Inc.'s 2034 outlook centres on $17.00, within a $11.31 to $27.68 range. That is up +16% on the projected 2033 average. That marks a +143% change versus current levels. Momentum favours further upside here.
By 2035, DTIL could reach as high as $33.96, with a base case around $20.52 and support toward $13.41 — roughly +194% from $6.99. Buyers look set to stay in control over this stretch.
Expect DTIL to range from $15.27 to $44.95 through 2040. The $25.37 average target implies a +263% move from current prices. That is up +24% on the projected 2035 average. Momentum favours further upside here.
The DTIL price prediction for 2050 points to an average of $51.63 (low $26.92, high $101.02) — a potential gain of +639% on today's $6.99. Buyers look set to stay in control over this stretch.
Investing $1,000 in DTIL today (≈ 143.061516 DTIL) could be worth
$7,386.05
+$6,386.05 (+639%) by 2050 · US Dollar
Based on the average projected DTIL price of $51.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DTILwould be worth at today's price.
$1,000 invested in DTIL on Jul 31, 2025 (≈ 210.526316 DTIL) would be worth
$1,471.58
+$471.58 (+47.2%) today · 1.47× · US Dollar
Based on a DTIL entry price of $4.75 vs. today's $6.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.29 | $958.85 | -4.1% |
| 1 month ago | $7.88 | $887.06 | -11.3% |
| 3 months ago | $7.28 | $960.16 | -4.0% |
| 6 months ago | $3.98 | $1,756.28 | +75.6% |
| 1 year ago | $4.75 | $1,471.58 | +47.2% |
| All time (5.0y) ago | $299.4 | $23.35 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DTIL forecast.
Our base-case forecast reaches $14.00 around 2033.
Implied market cap at $14.00: $361.23M
The multi-year outlook provides a trajectory of rising averages and strong upside potential. In 2026 the min/avg/max forecast is $3.57 / $7.36 / $10.13, with an initial neutral sentiment. From 2027 onward, the forecasts are bullish, with the 2027 avg at $11.37 and 2028 at $11.95, rising to 2029 at $13.21 and 2030 at $14.67, and then 2031 at $14.19 and 2032 at $16.81.
By 2033 the avg is $19.57 and the max is $33.23, with 2034 at $23.28 and 2035 at $29.09, continuing to 2040 where the avg is $37.22 and the max $71.06. The 2050 forecast shows an avg of $80.10 and a max of $170.96, with a headline ROI of 988.3% and bullish sentiment.
These figures represent estimates, not guarantees, and reflect expectations for growth under the stated assumptions. Risks and uncertainties inherent in a clinical-stage healthcare stock apply, and actual results may differ from forecasted outcomes.
Tap a question to reveal the answer.
Avg $14.67; min $10.09; max $23.11; ROI 99.3%; sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $11.37; 2030 avg $14.67; 2040 avg $37.22; 2050 avg $80.10). These are estimates, not guarantees.
Yes, the 2030 max forecast is $23.11.
Current price $7.36; Market cap $189.9M.
Low $5.70; High $9.50.
Precision BioSciences, Inc. Community Discussion
0Share your Precision BioSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.